Impact of Bariatric Surgery in Patients With Morbid Obesity (IVBIA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04009356|
Recruitment Status : Not yet recruiting
First Posted : July 4, 2019
Last Update Posted : July 8, 2019
The main objective is to compare the prevalence of anal incontinence (AI) before and after bariatric surgery in obese patients.
Inclusion: Patients who are scheduled for a bariatric surgical procedure after a multidisciplinary evaluation for about 1 year (following french national recommendations).
Primary objective: After inclusion, all patients will fill in a specific self-questionnaire evaluating AI (PFDI-20 score) before surgery and at 6 months after surgery.
Investigators will evaluate the prevalence of anal incontinence before and at 6months after surgery using this PFDI- 20 score.
In those patients with preoperative anal incontinence (only in patients with 3 positive answers to question n°9,10, and 11 of PFDI-20 score self-questionnaire), a pelvic MRI will be performed before and at 6 months after surgery. Consequently, no further imaging exam will be performed in patients without preoperative anal incontinence (less than 3 positive answers to question n°9,10, and 11),
- to evaluate the AI severity variation before and at 6 months after bariatric surgery regarding the percentage of postoperative weight loss.
- to compare the quality of life (PFIQ-7 score) related to AI day before and at 6 months after bariatric surgery.
|Condition or disease||Intervention/treatment|
|Obesity, Morbid Anal Incontinence Image, Body||Procedure: bariatric surgical procedures|
This study is proposed to all obese patients evaluated for potential bariatric surgery during a multidisciplinary evaluation for about 1 year following current french national recommendations.
Demographics are collected from medical records (age, sex, weight, height, diabetes, sleep apnea syndrome, hypertension, lipid disorders, distal neuropathy, depression, number of pregnancies, history of vaginal delivery, traumatic delivery, caesarean section, hysterectomy, urinary incontinence surgery, proctologic surgery, presence of rectal prolapse (operated or not), cholecystectomy, digestive resection, menopause, history of urinary or fecal or gaseous leakage, current treatments, tobacco consumption, diet.
Data are collected by self-questionnaire to all included patient during the preoperative consultation (about 6 weeks before bariatric surgery) and during the 6-months postoperative clinical visit scheduled during the regular follow-up.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Impact of Bariatric Surgery in Patients With Morbid Obesity. Prospective Study With Comparison Before and After|
|Estimated Study Start Date :||August 1, 2019|
|Estimated Primary Completion Date :||August 1, 2021|
|Estimated Study Completion Date :||February 1, 2022|
- Procedure: bariatric surgical procedures
gastric bypass, sleeve, banding,biliopancreatic diversion
- Prevalence of anal incontinence before and after bariatric surgery (%) [ Time Frame: at 6 month postoperatively ]PFDI-20 score (pelvic floor distress inventory) from zero to 12 (0: no incontinence and 12: severe incontinence)
- Severity of anal incontinence before and after surgery (score) [ Time Frame: at 6 month postoperatively ]PFDI-20 score (pelvic floor distress inventory) from zero to 12 (0: no incontinence and 12: severe incontinence)
- quality of life related to anal incontinence (score) [ Time Frame: at 6 month postoperatively ]PFIQ-7 (pelvic floor impact questionnaire) from 0 to 16 (0: no incontinence and 16: severe incontinence)
- Pelvic imaging (MRI) [ Time Frame: before and at 6 month postoperatively ]MRI
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04009356
|Contact: agathe Postillon, MD||0383153109 ext +email@example.com|
|Contact: laurent Brunaud, MD||0383153109 ext +firstname.lastname@example.org|